Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Tax Provisions of $230.9 million for Q2 2026, up 81.67% year-over-year from $127.1 million in Q2 2025, and up 122.02% quarter-over-quarter from $104.0 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $230.9 million for Q2 2026.
- In Q2 2026, Tax Provisions rose 81.67% year-over-year to $230.9 million; the TTM figure through Jun 2026 stood at $837.3 million (up 101.18% YoY), while the FY2025 annual figure was $725.8 million, up 97.6% from the prior year.
- Tax Provisions for Q2 2026 stood at $230.9 million, up from $104.0 million in the prior quarter.
- The five-year high for Tax Provisions was $303.3 million in Q3 2025, with the low at -$21.3 million in Q1 2024.
- The 5-year median for Tax Provisions is $112.8 million (2022), against an average of $121.9 million.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions sank 152.99% in 2024, then soared 552.11% in 2025.
- Regeneron Pharmaceuticals' Tax Provisions stood at $127.6 million in 2022, then slumped by 109.4% to -$12.0 million in 2023, then soared by 436.67% to $40.4 million in 2024, then surged by 392.82% to $199.1 million in 2025, then grew by 15.97% to $230.9 million in 2026.
- Business Quant data shows REGN's Tax Provisions at $230.9 million in Q2 2026, $104.0 million in Q1 2026, and $199.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 230.90 Mn |
| Mar 31, 2026 | 104.00 Mn |
| Dec 31, 2025 | 199.10 Mn |
| Sep 30, 2025 | 303.30 Mn |
| Jun 30, 2025 | 127.10 Mn |
| Mar 31, 2025 | 96.30 Mn |
| Dec 31, 2024 | 40.40 Mn |
| Sep 30, 2024 | 152.40 Mn |
| Jun 30, 2024 | 195.80 Mn |
| Mar 31, 2024 | -21.30 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | 103.00 Mn |
| Jun 30, 2023 | 114.50 Mn |
| Mar 31, 2023 | 40.20 Mn |
| Dec 31, 2022 | 127.60 Mn |
| Sep 30, 2022 | 194.10 Mn |
| Jun 30, 2022 | 111.10 Mn |
| Mar 31, 2022 | 87.60 Mn |
| Dec 31, 2021 | 274.40 Mn |
| Sep 30, 2021 | 184.40 Mn |